MedTrace Logo

Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors

NCT01105182 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2010-04-16

No results posted yet for this study

Summary

The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) combined with chemotherapy for pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA combined with chemotherapy for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).

Conditions

  • NSCLC
  • Pulmonary Metastases

Interventions

PROCEDURE

Radiofrequency Ablation

Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Jianxing He, MD, FACS · Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-12-31
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105182 on ClinicalTrials.gov